Study Finds Mannatech’s BounceBack(TM) Capsules Reduce Muscle Soreness*
Results of Randomized, Double-Blind, Placebo-Controlled, Crossover Human Study Published
COPPELL, Texas–(BUSINESS WIRE)–
Mannatech, Incorporated (NASDAQ:MTEX), a leading developer and provider of dietary supplements and skin care solutions, announced today that the results of a recent randomized, double-blind, placebo-controlled, crossover human study indicate that Mannatech’s BounceBack(TM) capsules significantly reduce muscle soreness after overexertion.*
These results complement the already established benefits of BounceBack(TM) capsules in reducing soreness and stiffness from physical activity, and supporting optimal joint and cartilage health.*
This human clinical study, presented at the 2008 International Society of Sports Nutrition Conference and Expo, was published on Sept. 17 in the Journal of the International Society of Sports Nutrition. It was stringently designed and conducted “to evaluate the ability of BounceBack(TM) capsules to reduce the signs and symptoms of DOMS (delayed onset muscle soreness) and increase the rate of muscle recovery following eccentric exercise.”*
“The design of this study achieves the gold standard of a randomized, blinded and well-controlled, product-specific human study,” said Dr. Robert A. Sinnott, senior vice president and chief science officer at Mannatech. “The wellness industry has come a long way since the passage of the Dietary Supplement Health and Education Act in 1994. While the burden of scientific proof has become more stringent, these changes are for the better. Consumers are insisting on access to high quality products with proven performance. This is just one of the ways that Mannatech is working to open new frontiers in the area of nutritional science.”
The results of this pilot study demonstrate “statistically significant differences in favor of BounceBack(TM) capsules for pain, tenderness and the amount of energy expended.”* Specifically, researchers concluded that BounceBack(TM) capsules “resulted in a significant reduction in standardized measures of pain and tenderness post-eccentric exercise, even after engaging in significantly more activity in the two-day period prior to the exercise protocol.”*
The research was conducted by Medicus Research LLC, a contract research organization based in Northridge, Calif. To view the study findings, please visit http://www.jissn.com/content/pdf/1550-2783-5-S1-P24.pdf or http://www.jissn.com/content/5/S1/P24.
The full scientific manuscript, including statistical analysis, has now been submitted for publication. Follow-on studies of this product are being planned to further explore beneficial structure-function activities.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Mannatech, Incorporated, is a global wellness solutions provider of innovative, high quality, proprietary dietary supplements, skin care products, and weight and fitness products sold through independent associates and members located in the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, Germany, South Africa and is scheduled to open in Singapore during the fourth quarter of 2008. For more information please visit www.mannatech.com or www.allaboutmannatech.com.
Please Note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
Source: Mannatech, Incorporated